ArticleTherapeutics and clinical risk management2012
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility.
Article in Therapeutics and clinical risk management, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Trial
- Article
- Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review.Journal of clinical medicine · 2021Review
- Osteonecrosis of the jaw in a patient under treatment of osteoporosis with oral bisphosphonate.Autopsy & case reports · 2020Article
- Do antiosteoporotic drugs improve bone regeneration in vivo?European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2020Article
- Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain.ClinicoEconomics and outcomes research : CEOR · 2015Article
- The clinical approach toward giant cell tumor of bone.The oncologist · 2014Review
- Periprosthetic bone loss: diagnostic and therapeutic approaches.F1000Research · 2013Review
- Treatment options for postmenopausal osteoporosis.Therapeutics and clinical risk management · 2012Article
- A Case Report of Ibandronic Acid Induced Non-Exposed BRONJ Involving the Maxillary Sinus.Journal of oral & maxillofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Denosumab is a breakthrough biological drug approved by the Food and Drug Administration and European Medicines Agency for the treatment of osteoporosis in 2010. It is a fully human monoclonal antireceptor activator of nuclear factor kappa-B ligand antibody, which inhibits the activity of osteoclasts, resulting in an antiresorptive effect with a significant increase in bone mineral density. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial, comparing denosumab with no treatment in 7868 women with postmenopausal osteoporosis, showed an important reduction of fracture risk at hip, vertebral, and nonvertebral sites in the treated group, while no statistically significant difference in the incidence of adverse events was detected between denosumab and placebo groups. The specific action of denosumab directed against a key regulator of osteoclasts makes it a valuable tool in preventing the occurrence of skeletal events caused by bone destruction in patients with advanced malignancies. The drug was approved for postmenopausal osteoporosis in women at increased risk of fracture and for the treatment of bone loss associated with androgen deprivation therapy in men with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.